Rise In Cardiovascular Diseases Driving The Growth Of The Market Due To Increasing Prevalence And Demand For Heart-Related Treatments: Pivotal Factor Influencing Cardiotonic Agents Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Cardiotonic Agents Market Size Growth Forecast: What to Expect by 2025?
Recently, there has been a swift expansion in the cardiotonic agents market size. A rise from $2.78 billion in 2024 to $3.11 billion in 2025, indicating a compound annual growth rate (CAGR) of 11.9% is expected. The historical period witnessed this growth due to factors like a surge in heart failure cases, an increasing elderly population, growing instances of coronary artery disease, the adoption of idle lifestyles, and an escalating pressure of hypertension and diabetes.

How Will the Cardiotonic Agents Market Size Evolve and Grow by 2029?
In the coming years, the cardiotonic agents market is set to experience a significant growth spurt, eventually reaching a value of $4.95 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 12.3%. This growth in the forecasted period can be credited to escalating rates of cardiovascular deaths, an increased number of clinical trials aimed at enhancing cardiotonic formulations, a rise in public-private collaborations in the field of cardiovascular drug creation, an uptick in hospital admissions due to cardiac issues, and growing demand for customized cardiovascular medicine. Future trends for this period include the development of peptide-based cardiotonic agents, the creation of dual-mechanism drugs, the integration of pharmacogenomics, innovation in the creation of injectable depot formulations, and the breakthroughs in combination therapies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cardiotonic-agents-global-market-report

What Drivers Are Propelling the Growth of Cardiotonic Agents Market Forward?
The increasing incidence of cardiovascular diseases is projected to boost the cardiotonic agents market's expansion. Cardiovascular diseases (CVDs), including coronary artery disease, heart failure, arrhythmias, and stroke, are disorders affecting the heart and blood vessels. An unhealthy diet that includes elevated amounts of saturated fats, trans fats, salt, and added sugars leads to obesity, hypertension, and high cholesterol levels, contributing to the rise in cardiovascular diseases. Cardiotonic agents help to augment the heart muscle's effectiveness and strength of contraction, promoting improved blood circulation and alleviating various cardiovascular disease symptoms. For example, data from the Australian Institute of Health and Welfare, a government entity in Australia, shows that certified deaths from coronary heart disease (CHD) in Australia climbed from 14,100 in 2021 to 14,900 in 2022. Consequently, the escalating prevalence of cardiovascular diseases is propelling the cardiotonic agents market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Cardiotonic Agents Market?
Major corporations engaged in the cardiotonic agents market are prioritizing the creation of innovative products like short-term inotropic drugs, designed to improve acute heart failure and cardiogenic shock through enhanced cardiac performance. These drugs function by temporarily boosting the heart's contraction capabilities, thus elevating cardiac output. In June 2023, a case in point is Hikma Pharmaceuticals plc, a UK-based pharmaceutical firm that introduced Dobutamine Injection, USP, in a vial of 250 mg/20 mL. This injection is meant for adults in need of short-term inotropic backup due to diminished heart contractility, often brought on by heart ailments or cardiac surgery aftermath. The mechanism behind this is the stimulation of beta-1 receptors which quickly enhances heart muscle contractility and cardiac output within 1-2 minutes. Typically delivered via an intravenous route, this injection is usually administered in a hospital environment under stringent supervision.

What Are the Key Segments in the Cardiotonic Agents Market?
The cardiotonic agents market covered in this report is segmented -

1) By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations
3) By Dosage Form: Tablet, Solution, Other Dosage Forms
4) By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C
2) By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone
3) By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine
4) By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine
5) By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24184&type=smp

Who Are the Key Players Shaping the Cardiotonic Agents Market's Competitive Landscape?
Major companies operating in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, Deccan Nutraceuticals Pvt. Ltd.

What Geographic Markets Are Powering Growth in the Cardiotonic Agents Market?
North America was the largest region in the cardiotonic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24184

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.